[go: up one dir, main page]

WO2002011695A3 - Poudres a inhaler de proteines en faisceau a quatre helices sechees par atomisation presentant une agregation reduite au minimum - Google Patents

Poudres a inhaler de proteines en faisceau a quatre helices sechees par atomisation presentant une agregation reduite au minimum Download PDF

Info

Publication number
WO2002011695A3
WO2002011695A3 PCT/US2001/024632 US0124632W WO0211695A3 WO 2002011695 A3 WO2002011695 A3 WO 2002011695A3 US 0124632 W US0124632 W US 0124632W WO 0211695 A3 WO0211695 A3 WO 0211695A3
Authority
WO
WIPO (PCT)
Prior art keywords
inhaleable
spray dried
helix bundle
protein powders
bundle protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/024632
Other languages
English (en)
Other versions
WO2002011695A2 (fr
Inventor
Cynthia Stevenson
Jayne E Hastedt
S Russ Lehrman
Hi-Shi Chiang
David B Bennett
David Lesikar
Bing Yang
David Gong
Kirsten Cabot
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nektar Therapeutics
Original Assignee
Inhale Therapeutics Systems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inhale Therapeutics Systems Inc filed Critical Inhale Therapeutics Systems Inc
Priority to MXPA03001092A priority Critical patent/MXPA03001092A/es
Priority to EP01959572A priority patent/EP1309312A2/fr
Priority to AU8111301A priority patent/AU8111301A/xx
Priority to CA002418960A priority patent/CA2418960A1/fr
Priority to JP2002517033A priority patent/JP2004515467A/ja
Priority to KR10-2003-7001831A priority patent/KR20030038690A/ko
Priority to AU2001281113A priority patent/AU2001281113B2/en
Publication of WO2002011695A2 publication Critical patent/WO2002011695A2/fr
Publication of WO2002011695A3 publication Critical patent/WO2002011695A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B41—PRINTING; LINING MACHINES; TYPEWRITERS; STAMPS
    • B41J—TYPEWRITERS; SELECTIVE PRINTING MECHANISMS, i.e. MECHANISMS PRINTING OTHERWISE THAN FROM A FORME; CORRECTION OF TYPOGRAPHICAL ERRORS
    • B41J29/00—Details of, or accessories for, typewriters or selective printing mechanisms not otherwise provided for
    • B41J29/12—Guards, shields or dust excluders
    • B41J29/13—Cases or covers
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09D—COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
    • C09D11/00—Inks
    • C09D11/30—Inkjet printing inks

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Materials Engineering (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PCT/US2001/024632 2000-08-07 2001-08-06 Poudres a inhaler de proteines en faisceau a quatre helices sechees par atomisation presentant une agregation reduite au minimum Ceased WO2002011695A2 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
MXPA03001092A MXPA03001092A (es) 2000-08-07 2001-08-06 Polvos de proteina de haz de 4 helices secados por rocio, inhalables, que tienen agregacion minimizada.
EP01959572A EP1309312A2 (fr) 2000-08-07 2001-08-06 Poudres a inhaler de proteines en faisceau a quatre helices sechees par atomisation presentant une agregation reduite au minimum
AU8111301A AU8111301A (en) 2000-08-07 2001-08-06 Inhaleable spray dried 4-helix bundle protein powders having minimized aggregation
CA002418960A CA2418960A1 (fr) 2000-08-07 2001-08-06 Poudres a inhaler de proteines en faisceau a quatre helices sechees par atomisation presentant une agregation reduite au minimum
JP2002517033A JP2004515467A (ja) 2000-08-07 2001-08-06 吸入可能な、噴霧乾燥した、最少の凝集物を有する４−ヘリックスバンドルタンパク質粉末
KR10-2003-7001831A KR20030038690A (ko) 2000-08-07 2001-08-06 응집이 최소화된, 흡입성 분무 건조 4-나선 다발 단백질분말
AU2001281113A AU2001281113B2 (en) 2000-08-07 2001-08-06 Inhaleable spray dried 4-helix bundle protein powders having minimized aggregation

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US22314400P 2000-08-07 2000-08-07
US60/223,144 2000-08-07
US22863400P 2000-08-29 2000-08-29
US60/228,634 2000-08-29
US24047800P 2000-10-13 2000-10-13
US60/240,478 2000-10-13

Publications (2)

Publication Number Publication Date
WO2002011695A2 WO2002011695A2 (fr) 2002-02-14
WO2002011695A3 true WO2002011695A3 (fr) 2002-04-25

Family

ID=27397184

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/024632 Ceased WO2002011695A2 (fr) 2000-08-07 2001-08-06 Poudres a inhaler de proteines en faisceau a quatre helices sechees par atomisation presentant une agregation reduite au minimum

Country Status (10)

Country Link
US (3) US6569406B2 (fr)
EP (1) EP1309312A2 (fr)
JP (1) JP2004515467A (fr)
KR (1) KR20030038690A (fr)
CN (1) CN1446077A (fr)
AU (2) AU8111301A (fr)
CA (1) CA2418960A1 (fr)
MX (1) MXPA03001092A (fr)
TW (1) TWI283182B (fr)
WO (1) WO2002011695A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6749835B1 (en) 1999-08-25 2004-06-15 Advanced Inhalation Research, Inc. Formulation for spray-drying large porous particles
US6956021B1 (en) 1998-08-25 2005-10-18 Advanced Inhalation Research, Inc. Stable spray-dried protein formulations
US7182961B2 (en) 2001-11-20 2007-02-27 Advanced Inhalation Research, Inc. Particulate compositions for pulmonary delivery

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT679088E (pt) * 1992-09-29 2002-12-31 Inhale Therapeutic Syst Administracao pulmonar de fragmentos activos de hormona paratiroide
JPH10501519A (ja) 1994-03-07 1998-02-10 インヘイル・セラピューティック・システムズ インシュリンを肺に送給できる方法および組成物
US20030113273A1 (en) * 1996-06-17 2003-06-19 Patton John S. Methods and compositions for pulmonary delivery of insulin
CA2190502A1 (fr) * 1994-05-18 1995-11-23 Robert M. Platz Procedes et compositions pour produire des interferons sous forme de poudre seche
US6290991B1 (en) * 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
US20030035778A1 (en) * 1997-07-14 2003-02-20 Robert Platz Methods and compositions for the dry powder formulation of interferon
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
CA2382133C (fr) 2000-05-10 2010-11-23 Alliance Pharmaceutical Corporation Poudres a base de phospholipides permettant de distribuer un medicament
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
JP4147234B2 (ja) 2004-09-27 2008-09-10 キヤノン株式会社 吐出用液体、吐出方法、カートリッジ及び吐出装置
JP2005518430A (ja) * 2001-11-19 2005-06-23 ベクトン・ディキンソン・アンド・カンパニー 微粒子形態の薬剤組成物
EP1458360B1 (fr) 2001-12-19 2011-05-11 Novartis AG Administration pulmonaire d'aminoglycosides
US20050163725A1 (en) * 2002-03-20 2005-07-28 Blizzard Charles D. Method for administration of growth hormone via pulmonary delivery
AU2003218308B2 (en) * 2002-03-20 2006-07-20 Advanced Inhalation Research, Inc. hGH (human growth hormone) formulations for pulmonary administration
ATE385193T1 (de) 2002-03-20 2008-02-15 Mannkind Corp Inhalationsgerät
US7008644B2 (en) * 2002-03-20 2006-03-07 Advanced Inhalation Research, Inc. Method and apparatus for producing dry particles
US20050037047A1 (en) * 2003-08-11 2005-02-17 Young-Ho Song Medical devices comprising spray dried microparticles
JP2006199589A (ja) * 2003-09-03 2006-08-03 Ltt Bio-Pharma Co Ltd 生理活性タンパク質またはペプチドを含有するナノ粒子およびその製造方法、ならびに当該ナノ粒子からなる外用剤
US7024866B2 (en) * 2003-12-11 2006-04-11 Helix Technology Corporation Axial loaded seal system with a static L-seal
US20050191246A1 (en) * 2003-12-13 2005-09-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Powders comprising low molecular dextran and methods of producing those powders
JP2007522246A (ja) * 2004-02-12 2007-08-09 ネクター セラピューティクス インターロイキン−１３拮抗剤粉末剤、スプレードライ粒子、及び方法
JO3102B1 (ar) * 2004-03-17 2017-09-20 Chiesi Framaceutici S P A صيغ صيدلانية لوسائل استنشاق بها مسحوق جاف تشتمل على مكون فعال بقوة منخفضة الجرعة
EP1740213B9 (fr) * 2004-04-07 2012-06-13 Ares Trading S.A. Formulation liquide avec une hormone de croissance
DE102004022927A1 (de) * 2004-05-10 2005-12-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg 1,4 O-verknüpfte Saccharose-Derivate zur Stabilisierung von Antikörpern oder Antikörper-Derivaten
DK1786784T3 (da) 2004-08-20 2011-02-14 Mannkind Corp Katalyse af diketopiperazinsyntese
BRPI0514293B1 (pt) 2004-08-23 2022-07-19 Mannkind Corporation Sistema microparticulado para distribuição de droga
JP4147235B2 (ja) 2004-09-27 2008-09-10 キヤノン株式会社 吐出用液体、吐出方法、液滴化方法、液体吐出カートリッジ及び吐出装置
WO2006071102A1 (fr) * 2004-12-30 2006-07-06 Dobeel Co., Ltd. Préparation séchée par atomisation contenant des protéines de la famille de la collectine ou des variantes desdites protéines, et procédé d'élaboration de ladite préparation
DK1928423T3 (en) 2005-09-14 2016-02-29 Mannkind Corp A method for drug formulation based on increasing the affinity of the active substances to the crystalline microparticle surfaces
CA2643464C (fr) 2006-02-22 2018-09-04 Mannkind Corporation Procede pour ameliorer les proprietes pharmaceutiques de microparticules comprenant de la dicetopiperazine et un agent actif
TW200806317A (en) * 2006-03-20 2008-02-01 Wyeth Corp Methods for reducing protein aggregation
US20080035141A1 (en) * 2006-06-16 2008-02-14 Warner W R Aerosolized therapy kit
DE102006030164A1 (de) 2006-06-29 2008-01-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Inhalative Pulver
JP2008044935A (ja) * 2006-07-20 2008-02-28 Sicor Inc 固体状無菌活性医薬成分を製造する方法
US7746769B2 (en) * 2007-03-26 2010-06-29 Alcatel Lucent Management of redundant and multi-segment pseudo-wire
MX2009010361A (es) 2007-03-29 2009-10-16 Abbott Lab Anticuerpos il-12 anti-humanos cristalinos.
EP2050437A1 (fr) * 2007-10-15 2009-04-22 Laboratoires SMB Compositions de poudre sèche pharmaceutiquement améliorées pour l'inhalation
WO2011163272A1 (fr) 2010-06-21 2011-12-29 Mannkind Corporation Système et procédé d'administration de médicament sous la forme d'une poudre sèche
US20090145433A1 (en) * 2007-12-08 2009-06-11 Michael James Apparatus for dispensing a powdered composition into the aerodigestive tract
JP6078217B2 (ja) * 2008-01-15 2017-02-08 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー 粉末化されたタンパク質組成物及びその作製方法
CN106039494B (zh) 2008-06-13 2019-12-24 曼金德公司 干粉吸入器和用于药物输送的系统
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
BRPI0914308B8 (pt) 2008-06-20 2021-06-22 Mannkind Corp sistema de inalação
TWI614024B (zh) 2008-08-11 2018-02-11 曼凱公司 超快起作用胰島素之用途
CA2748490C (fr) 2008-12-29 2016-10-04 Mannkind Corporation Analogues substitues de dicetopiperazine pour une utilisation en tant qu'agents d'administration de medicaments
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
WO2010105094A1 (fr) 2009-03-11 2010-09-16 Mannkind Corporation Appareil, système et procédé de mesure de résistance d'un inhalateur
MY186975A (en) 2009-06-12 2021-08-26 Mannkind Corp Diketopiperazine microparticles with defined specific surface areas
EP2496295A1 (fr) 2009-11-03 2012-09-12 MannKind Corporation Appareil et méthode de simulation d'efforts d'inhalation
WO2012051426A2 (fr) * 2010-10-15 2012-04-19 Glaxo Group Limited Formulations de médicament sous forme d'agrégats de nanoparticules, leur fabrication et leur utilisation
MY180552A (en) 2011-04-01 2020-12-02 Mannkind Corp Blister package for pharmaceutical cartridges
WO2012174472A1 (fr) 2011-06-17 2012-12-20 Mannkind Corporation Microparticules de dicétopipérazine de capacité élevée
WO2013001044A1 (fr) * 2011-06-28 2013-01-03 Leukocare Ag Procédé de prévention du dépliement d'un (poly)peptide et/ou d'induction du (re)pliement d'un (poly)peptide
JP6018640B2 (ja) 2011-10-24 2016-11-02 マンカインド コーポレイション 疼痛を緩和するのに有効な鎮痛組成物並びに当該組成物を含む乾燥粉末及び乾燥粉末薬剤輸送システム
EP4026543B1 (fr) 2011-11-18 2024-08-07 Regeneron Pharmaceuticals, Inc. Microparticules protéiques recouvertes de polymères pour formulations à libération prolongée pour une utilisation dans le corps vitré pour le traitement de troubles oculaires vasculaires
JP6267685B2 (ja) 2012-04-13 2018-01-24 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 集合粒子
DK2872205T3 (en) 2012-07-12 2017-02-27 Mannkind Corp DRY POWDER FORMAL ADMINISTRATION SYSTEM
WO2014066856A1 (fr) 2012-10-26 2014-05-01 Mannkind Corporation Compositions et procédés de vaccin antigrippal inhalable
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
KR102391750B1 (ko) 2013-03-15 2022-04-28 맨카인드 코포레이션 미세결정성 디케토피페라진 조성물 및 방법
US10149823B2 (en) 2013-04-30 2018-12-11 Otitopic Inc. Dry powder formulations and methods of use
EP3021834A1 (fr) 2013-07-18 2016-05-25 MannKind Corporation Compositions pharmaceutiques en poudre sèche stables à la chaleur et procédés
US11446127B2 (en) 2013-08-05 2022-09-20 Mannkind Corporation Insufflation apparatus and methods
AR097762A1 (es) * 2013-09-27 2016-04-13 Intervet Int Bv Formulaciones secas de vacunas que son estables a temperatura ambiente
JP6701086B2 (ja) 2014-02-20 2020-05-27 オティトピック インコーポレイテッド 吸入用の乾燥粉末製剤
EP3107606B1 (fr) * 2014-02-21 2024-08-28 David Brown Dispositif d'inhalation pour inhaler des poudres
WO2015148905A1 (fr) 2014-03-28 2015-10-01 Mannkind Corporation Utilisation d'insuline à action ultrarapide
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
GB201419900D0 (en) * 2014-11-07 2014-12-24 Dupont Nutrition Biosci Aps Method
US11224594B2 (en) * 2015-09-16 2022-01-18 Philip Morris Products S.A. Nicotine formulations and methods of making and using the same
US9585835B1 (en) * 2015-09-16 2017-03-07 Sansa Corporation (Barbados) Inc. Inhalable nicotine formulations and methods of making and using the same
US20190133940A1 (en) * 2016-06-30 2019-05-09 Philip Morris Products S.A. Nicotine particles and compositions
EP3592352A1 (fr) * 2017-03-07 2020-01-15 Philip Morris Products S.a.s. Formulations de nicotine à inhaler et procédés de production et d'utilisation de celles-ci
JP7637618B2 (ja) * 2018-11-21 2025-02-28 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 高濃度タンパク質製剤
CN111598399B (zh) * 2020-04-17 2023-04-28 西安理工大学 基于分布式计算平台的超大规模输电网络扩展规划方法
KR20230125383A (ko) 2022-02-21 2023-08-29 주식회사 홀블렌딩 식물성 단백질 파우더 및 그 제조방법

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000000176A1 (fr) * 1998-06-30 2000-01-06 Quadrant Healthcare (Uk) Limited Formulation a microparticules pour inhalation
US6051256A (en) * 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
WO2001032144A1 (fr) * 1999-10-29 2001-05-10 Inhale Therapeutic Systems, Inc. Compositions de poudre seche a dispersivite amelioree

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES8702440A1 (es) 1984-10-04 1986-12-16 Monsanto Co Un procedimiento para la preparacion de una composicion de polipeptido inyectable sustancialmente no acuosa.
IL79681A (en) 1985-08-12 1991-06-10 Int Minerals & Chem Corp Transition metal complexes of growth hormones and their prolonged release compositions
US4917685A (en) 1986-05-16 1990-04-17 International Minerals & Chem. Corp. Delivery device for the administration of stabilized growth promoting hormones
ATE76311T1 (de) 1986-08-19 1992-06-15 Genentech Inc Einrichtung und dispersion zum intrapulmonalen eingeben von polypeptidwuchsstoffen und zytokinen.
ES2044941T5 (es) 1987-08-21 1999-02-16 Mallinckrodt Group Inc Estabilizador de hormonas promotoras del crecimiento.
CA1331133C (fr) 1988-03-01 1994-08-02 Michael Jon Pikal Formulations pharmaceutiques d'hormone de croissance humaine
US5763394A (en) 1988-04-15 1998-06-09 Genentech, Inc. Human growth hormone aqueous formulation
US5182258A (en) * 1989-03-20 1993-01-26 Orbon Corporation Systemic delivery of polypeptides through the eye
DK168790D0 (fr) 1990-07-13 1990-07-13 Novo Nordisk As
US5780599A (en) 1990-07-13 1998-07-14 Novo Nordisk A/S Growth hormone crystals and a process for production of growth hormone crystals
SE467525B (sv) 1990-10-09 1992-08-03 Nemo Ivarson Ab Foerfarande foer att oeverdraga fasta partiklar i pulverform med ett i rumstemperatur hoegviskoest eller fast material
DK0564531T3 (da) 1990-12-03 1998-09-28 Genentech Inc Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber
AU1442592A (en) 1991-02-20 1992-09-15 Nova Pharmaceutical Corporation Controlled release microparticulate delivery system for proteins
WO1992017200A2 (fr) 1991-03-28 1992-10-15 Genentech, Inc. Formulations stables a base d'ion metal et d'hormone de croissance
ATE119805T1 (de) 1991-07-11 1995-04-15 Glatt Gmbh Verfahren und einrichtung zum beschichten von teilchen.
DK204791D0 (da) 1991-12-20 1991-12-20 Novo Nordisk As Hidtil ukendt farmaceutisk praeparat
US6022858A (en) 1991-12-20 2000-02-08 Novo Nordisk A/S Pharmaceutical formulation of human-growth hormone pretreated with zinc salt
US5849700A (en) 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
US5849704A (en) 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
DK0618807T3 (da) 1991-12-20 2003-03-03 Novo Nordisk As Stabiliseret farmaceutisk formulering omfattende human væksthormon og histidin
WO1993013792A1 (fr) 1992-01-13 1993-07-22 Pitman-Moore, Inc. Dispositif de liberation retard de complexes constitues par un metal de transition et une proteine
SE9201073D0 (sv) 1992-04-03 1992-04-03 Kabi Pharmacia Ab Protein formulation
US6582728B1 (en) * 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
CA2150803C (fr) 1992-12-02 2006-01-31 Henry Auer Hormone de croissance a liberation controlee qui contient des microspheres
US5589167A (en) 1993-02-23 1996-12-31 Genentech, Inc. Excipient stabilization of polypeptides treated with organic solvents
JP3349540B2 (ja) 1993-03-10 2002-11-25 フロイント産業株式会社 造粒方法および装置
US5849535A (en) 1995-09-21 1998-12-15 Genentech, Inc. Human growth hormone variants
IS1796B (is) 1993-06-24 2001-12-31 Ab Astra Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband
JPH08512056A (ja) 1993-06-30 1996-12-17 ジェネンテク・インコーポレイテッド リポソームの製造法
JPH07232049A (ja) 1994-02-25 1995-09-05 Freunt Ind Co Ltd 遠心転動造粒コーティング装置および粉粒体の遠心転動造粒コーティング方法ならびにその方法を用いた粉粒体の造粒方法とコーティング方法
JP2886446B2 (ja) 1994-03-03 1999-04-26 関西ペイント株式会社 塗膜保護用シート
WO1995035116A1 (fr) 1994-06-17 1995-12-28 Applied Research Systems Compositions pharmaceutiques renfermant l'hch
US5641510A (en) 1994-07-01 1997-06-24 Genentech, Inc. Method for treating capsules used for drug storage
US5654278A (en) 1994-10-13 1997-08-05 Novo Nordisk A/S Composition and method comprising growth hormone and leucine
IL115592A (en) 1994-10-13 2000-07-26 Novo Nordisk As Stabilized pharmaceutical formulation comprising a growth hormone and leucine
US5631225A (en) 1994-10-13 1997-05-20 Novo Nordisk A/S Pharmaceutical formulation
US5547696A (en) 1994-10-13 1996-08-20 Novo Nordisk A/S Pharmaceutical formulation
SE9404468D0 (sv) 1994-12-22 1994-12-22 Astra Ab Powder formulations
US6524557B1 (en) 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
US5705482A (en) 1995-01-13 1998-01-06 Novo Nordisk A/S Pharmaceutical formulation
ZA96122B (en) 1995-01-13 1996-07-24 Novo Nordisk As A pharmaceutical formulation
KR19980701351A (ko) 1995-01-13 1998-05-15 슈타르 피아 성장호르몬 및 Ｘ-Ｌｙｓ를 함유하는 안정화된 약제조제물(A STABILIZED PHARMACEUTICAL FORMULATION COMPRISING A GROWTH HORMONE AND X-Lys
US6004583A (en) 1995-03-22 1999-12-21 Orex Pharmaceutical Development Corp. Protein-containing polymer composition for oral administration
US5552385A (en) 1995-06-05 1996-09-03 Novo Nordisk A/S Pharmaceutical formulation
ZA965367B (en) 1995-07-12 1997-01-23 Novo Nordisk As A pharmaceutical formulation
ZA965368B (en) 1995-07-14 1997-01-14 Novo Nordisk As A pharmaceutical formulation
US20020077461A1 (en) 1996-04-24 2002-06-20 Soren Bjorn Pharmaceutical formulation
JP3839531B2 (ja) 1996-11-05 2006-11-01 フロイント産業株式会社 遠心転動造粒コーティング装置およびこれを用いた粉粒体の造粒方法ならびにコーティング方法
US6191107B1 (en) 1997-09-26 2001-02-20 Takeda Chemical Industries, Ltd. Complex of human growth hormone and zinc
AU758351B2 (en) 1998-08-25 2003-03-20 Alkermes, Inc. Stable spray-dried protein formulations
US6197369B1 (en) 1999-09-30 2001-03-06 New Jersey Institute Of Technology Method of particle coating
US6555660B2 (en) * 2000-01-10 2003-04-29 Maxygen Holdings Ltd. G-CSF conjugates

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6051256A (en) * 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
WO2000000176A1 (fr) * 1998-06-30 2000-01-06 Quadrant Healthcare (Uk) Limited Formulation a microparticules pour inhalation
WO2001032144A1 (fr) * 1999-10-29 2001-05-10 Inhale Therapeutic Systems, Inc. Compositions de poudre seche a dispersivite amelioree

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6956021B1 (en) 1998-08-25 2005-10-18 Advanced Inhalation Research, Inc. Stable spray-dried protein formulations
US6749835B1 (en) 1999-08-25 2004-06-15 Advanced Inhalation Research, Inc. Formulation for spray-drying large porous particles
US7182961B2 (en) 2001-11-20 2007-02-27 Advanced Inhalation Research, Inc. Particulate compositions for pulmonary delivery
US7384649B2 (en) 2001-11-20 2008-06-10 Advanced Inhalation Research, Inc. Particulate compositions for pulmonary delivery

Also Published As

Publication number Publication date
JP2004515467A (ja) 2004-05-27
US20030190291A1 (en) 2003-10-09
US6838075B2 (en) 2005-01-04
AU8111301A (en) 2002-02-18
TWI283182B (en) 2007-07-01
US6569406B2 (en) 2003-05-27
WO2002011695A2 (fr) 2002-02-14
US20020065399A1 (en) 2002-05-30
KR20030038690A (ko) 2003-05-16
US20050186143A1 (en) 2005-08-25
CN1446077A (zh) 2003-10-01
EP1309312A2 (fr) 2003-05-14
MXPA03001092A (es) 2003-09-25
CA2418960A1 (fr) 2002-02-14
AU2001281113B2 (en) 2006-07-20

Similar Documents

Publication Publication Date Title
AU8111301A (en) Inhaleable spray dried 4-helix bundle protein powders having minimized aggregation
EP1307256A4 (fr) Inhalateur de poudre seche
SI1294421T1 (sl) Suhoprašni inhalator
ZA200105453B (en) Potentiation of Anti-CD38-immunotoxin cytotoxicity.
AU1331802A (en) Cd38 modulated chemotaxis
AU2188402A (en) Delta 1-pyrrolines used as pesticides
AU2002225664A1 (en) A sprayer container comprising a fabric treatment composition
GB2373455B (en) Dynamic collapsible revolving toy
GB2352736B (en) Sparkle linen spray
TW543764U (en) Rotary dryer
AU146091S (en) Hair dryer
GB0001115D0 (en) Hand dryer
HRPK20000355B1 (en) Electro-compressor knapsack sprayer
AU1752601A (en) Dry powder inhaler
IL153556A0 (en) Novispirins: antimicrobial peptides
EP1444916A4 (fr) Sechoir
HUP0302964A3 (en) Delta 1-pyrrolines, intermediates, preparation thereof and their use as pesticides
GB2365335B (en) Hairdryer
GB0113028D0 (en) Powder applicator
GB0000482D0 (en) Enteric coated pharmaceutical formulation
GB2397305B (en) Sparkle linen spray
GB0017444D0 (en) Dry sprayer
TW416265U (en) Improved sprayer
AU145498S (en) Lotion sprayer
AU145494S (en) Lotion sprayer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2001281113

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 018137962

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/001092

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2418960

Country of ref document: CA

Ref document number: 2002517033

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 1020037001831

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2001959572

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001959572

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020037001831

Country of ref document: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642